These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 31083520)

  • 1. Identifying the Pathological Domain of Alpha- Synuclein as a Therapeutic for Parkinson's Disease.
    Shen N; Song G; Yang H; Lin X; Brown B; Hong Y; Cai J; Cao C
    Int J Mol Sci; 2019 May; 20(9):. PubMed ID: 31083520
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Generation and characterization of novel conformation-specific monoclonal antibodies for α-synuclein pathology.
    Vaikath NN; Majbour NK; Paleologou KE; Ardah MT; van Dam E; van de Berg WD; Forrest SL; Parkkinen L; Gai WP; Hattori N; Takanashi M; Lee SJ; Mann DM; Imai Y; Halliday GM; Li JY; El-Agnaf OM
    Neurobiol Dis; 2015 Jul; 79():81-99. PubMed ID: 25937088
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cofilin 1 promotes the aggregation and cell-to-cell transmission of α-synuclein in Parkinson's disease.
    Yan M; Meng L; Dai L; Zhang X; Chen G; Zheng Y; Zha Y; Zeng Y; Zhang Z
    Biochem Biophys Res Commun; 2020 Sep; 529(4):1053-1060. PubMed ID: 32819564
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alpha-synuclein fragments trigger distinct aggregation pathways.
    Chakroun T; Evsyukov V; Nykänen NP; Höllerhage M; Schmidt A; Kamp F; Ruf VC; Wurst W; Rösler TW; Höglinger GU
    Cell Death Dis; 2020 Feb; 11(2):84. PubMed ID: 32015326
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phenotypic manifestation of α-synuclein strains derived from Parkinson's disease and multiple system atrophy in human dopaminergic neurons.
    Tanudjojo B; Shaikh SS; Fenyi A; Bousset L; Agarwal D; Marsh J; Zois C; Heman-Ackah S; Fischer R; Sims D; Melki R; Tofaris GK
    Nat Commun; 2021 Jun; 12(1):3817. PubMed ID: 34155194
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alteration of Structure and Aggregation of α-Synuclein by Familial Parkinson's Disease Associated Mutations.
    Sahay S; Ghosh D; Singh PK; Maji SK
    Curr Protein Pept Sci; 2017; 18(7):656-676. PubMed ID: 26972727
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Defining α-synuclein species responsible for Parkinson's disease phenotypes in mice.
    Froula JM; Castellana-Cruz M; Anabtawi NM; Camino JD; Chen SW; Thrasher DR; Freire J; Yazdi AA; Fleming S; Dobson CM; Kumita JR; Cremades N; Volpicelli-Daley LA
    J Biol Chem; 2019 Jul; 294(27):10392-10406. PubMed ID: 31142553
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fibrillar form of α-synuclein-specific scFv antibody inhibits α-synuclein seeds induced aggregation and toxicity.
    Gupta V; Salim S; Hmila I; Vaikath NN; Sudhakaran IP; Ghanem SS; Majbour NK; Abdulla SA; Emara MM; Abdesselem HB; Lukacsovich T; Erskine D; El-Agnaf OMA
    Sci Rep; 2020 May; 10(1):8137. PubMed ID: 32424162
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Two-step screening method to identify α-synuclein aggregation inhibitors for Parkinson's disease.
    Hideshima M; Kimura Y; Aguirre C; Kakuda K; Takeuchi T; Choong CJ; Doi J; Nabekura K; Yamaguchi K; Nakajima K; Baba K; Nagano S; Goto Y; Nagai Y; Mochizuki H; Ikenaka K
    Sci Rep; 2022 Jan; 12(1):351. PubMed ID: 35013421
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Physicochemical characterization of the G51D mutation of α-synuclein that is responsible for its severe cytotoxicity.
    Murata T; Tochio N; Utsunomiya-Tate N
    Neurosci Lett; 2021 Aug; 760():136077. PubMed ID: 34161822
    [TBL] [Abstract][Full Text] [Related]  

  • 11. α-Synuclein Fibrils Exhibit Gain of Toxic Function, Promoting Tau Aggregation and Inhibiting Microtubule Assembly.
    Oikawa T; Nonaka T; Terada M; Tamaoka A; Hisanaga S; Hasegawa M
    J Biol Chem; 2016 Jul; 291(29):15046-56. PubMed ID: 27226637
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Complexation of NAC-Derived Peptide Ligands with the C-Terminus of α-Synuclein Accelerates Its Aggregation.
    Jha NN; Ranganathan S; Kumar R; Mehra S; Panigrahi R; Navalkar A; Ghosh D; Kumar A; Padinhateeri R; Maji SK
    Biochemistry; 2018 Feb; 57(5):791-804. PubMed ID: 29286644
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The chaperone activity of α-synuclein: Utilizing deletion mutants to map its interaction with target proteins.
    Rekas A; Ahn KJ; Kim J; Carver JA
    Proteins; 2012 May; 80(5):1316-25. PubMed ID: 22274962
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prion-like C-Terminal Domain of TDP-43 and α-Synuclein Interact Synergistically to Generate Neurotoxic Hybrid Fibrils.
    Dhakal S; Wyant CE; George HE; Morgan SE; Rangachari V
    J Mol Biol; 2021 May; 433(10):166953. PubMed ID: 33771571
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Loss in Toxic Function of Aggregates of α -Synuclein Mutants by a β-Synuclein Derived Peptide.
    Mohammadi S; Nikkhah M; Hosseinkhani S
    Protein Pept Lett; 2017; 24(8):757-764. PubMed ID: 28820063
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Proteomics analysis identifies phosphorylation-dependent alpha-synuclein protein interactions.
    McFarland MA; Ellis CE; Markey SP; Nussbaum RL
    Mol Cell Proteomics; 2008 Nov; 7(11):2123-37. PubMed ID: 18614564
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Membrane interactions of oligomeric alpha-synuclein: potential role in Parkinson's disease.
    van Rooijen BD; Claessens MM; Subramaniam V
    Curr Protein Pept Sci; 2010 Aug; 11(5):334-42. PubMed ID: 20423294
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibiting α-synuclein oligomerization by stable cell-penetrating β-synuclein fragments recovers phenotype of Parkinson's disease model flies.
    Shaltiel-Karyo R; Frenkel-Pinter M; Egoz-Matia N; Frydman-Marom A; Shalev DE; Segal D; Gazit E
    PLoS One; 2010 Nov; 5(11):e13863. PubMed ID: 21085664
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The C-terminal α-helices of mammalian Hsc70 play a critical role in the stabilization of α-synuclein binding and inhibition of aggregation.
    Chaari A; Eliezer D; Ladjimi M
    Int J Biol Macromol; 2016 Feb; 83():433-41. PubMed ID: 26601760
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CMT-3 targets different α-synuclein aggregates mitigating their toxic and inflammogenic effects.
    González-Lizárraga F; Ploper D; Ávila CL; Socías SB; Dos-Santos-Pereira M; Machín B; Del-Bel E; Michel PP; Pietrasanta LI; Raisman-Vozari R; Chehín R
    Sci Rep; 2020 Nov; 10(1):20258. PubMed ID: 33219264
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.